NCI-CONNECT Rare Brain & Spine Tumor Network

Rare Brain and Spine Tumor Clinical Studies

Credit: NCI-CONNECT Staff

NCI-CONNECT has a number of studies that are open for adult patients with rare central nervous system (CNS) cancers. Check back as we plan to add more.

Online Study

Outcomes and Risk Project for Patients with Rare CNS Cancers

The project aims to improve our understanding of outcomes and risk factors related to the occurrence of rare CNS cancers. Research shows that certain risk factors may increase a person’s chances of developing cancer. Factors can include exposure to chemicals or other substances, and personal and family medical history. If you take part in this study, you will complete a web-based survey and submit a saliva sample that will be used for genetic testing. 

Clinical Assessment

Evaluation of the Natural History and Specimen Banking for Patients with CNS Cancers

The study objective is to better understand brain and spinal cord tumors and uncover areas for further research. It also aims to connect patients with doctors who can help them manage their illness and give them new treatment options. 

Treatment Trials

Immune Checkpoint Inhibitor Nivolumab for Patients with Rare CNS Cancers

The clinical trial is investigating the immunotherapy drug nivolumab as an effective treatment for people with rare CNS tumors. 

Carboplatin and Bevacizumab for Patients with Ependymoma

The clinical trial is investigating the combination of bevacizumab and carboplatin to help control recurrent ependymoma.

  • Posted: September 17, 2018

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Rare Brain and Spine Tumor Clinical Studies was originally published by the National Cancer Institute.”

We welcome your comments on this post. All comments must follow our comment policy.